Mini Roches

Biotech companies looking to establish research partnerships with Roche may find the process a little easier under the companys proposed new R&D structure. The Swiss giant last week unveiled plans to introduce a disease-focused organization with flatter hierarchies in a bid to streamline decisions and speed up the throughput of compounds in the pipeline.

Roche (SWX:ROG, Basel, Switzerland) is reorganizing its research into five autonomous disease biology areas (DBAs), each with its own budget and the freedom to do deals and make acquisitions without having to seek permission from central HQ.

Read the full 903 word article

How to gain access

Continue reading with a
two-week free trial.